Marko Skelin

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 7

Top Topics

Combination Therapy

Aortic Dissection

Randomized Controlled Trial

Extracorporeal Membrane Oxygenation

Top Venues

International journal of clinical practice

European journal of heart failure

Journal of chemotherapy (Florence, Italy)

This page only lists publications with an associated author ORCID identifier.

Publications

Ivan Krecak, Sanja Klobucar Majanovic, Josipa Budimir, Marko Skelin, Marko Lucijanic
Diabetes mellitus, metformin, and the risk of MPN. Blood advances (2024)
Marko Skelin, David Šarčević, Dina Lešin Gaćina, Iva Mucalo, Ivo Dilber, Eugen Javor
The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis. Journal of chemotherapy (Florence, Italy) (2022)
Eugen Javor, Ali Allouch, Josipa Osvaldić Galic, Marko Skelin
The economic impact of a clinical pharmacist's involvement in the hospital medicines policy in a rural area. International journal of clinical practice 75 (11) (2021)
Marko Skelin, Dario Rahelić, Petar Skelin, Marko Lucijanic
Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920. Diabetes care 43 (2) (2020)
Marko Skelin, Marko Lucijanic, Jelena Lucijanic
Dyslipidaemia, a factor worthy of adjustment. European journal of heart failure 22 (3) (2019)
Marko Skelin, Eugen Javor, Marko Lucijanić, Tomo Lucijanić, Lejsa Jakupović, Dario Rahelić
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients. International journal of clinical practice 72 (12) (2018)
Marko Skelin, Tomo Lucijanić, Ana-Marija Liberati-Čizmek, Sanja Majanović Klobučar, Marko Lucijanić, Lejsa Jakupović, Miro Bakula, Jelena Vučak Lončar, Srečko Marušić, Tomas Matić, Željko Romić, Jerka Dumić, Dario Rahelić
Effect of timing of levothyroxine administration on the treatment of hypothyroidism: a three-period crossover randomized study. Endocrine 62 (2) (2018)